Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
Open Access
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 130, 179-186
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 40 references indexed in Scilit:
- New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical ManagementJournal of Thoracic Oncology, 2018
- Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumorsNature Communications, 2018
- Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment OutcomeClinical Cancer Research, 2018
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2017
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like SubsetsClinical Cancer Research, 2016
- Clinical features of large cell neuroendocrine carcinoma: a population-based overviewEuropean Respiratory Journal, 2015
- Neuroendocrine Neoplasms of the Lung: A Prognostic SpectrumJournal of Clinical Oncology, 2006
- Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the LungJournal of Clinical Oncology, 2005
- Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven casesThe Journal of Thoracic and Cardiovascular Surgery, 2002